Ketamine Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.
Inquirer on MSN2d
Controlled drug Ketamine a lifeline for patients with severe depression in S’poreKetamine therapy is now a mainstream prescription for treatment-resistant depression. Read more at straitstimes.com.
12h
California gastroenterologist Dr. Saurabh Sethi has called out three popular drinks that increase the risk of Alzheimer’s.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback